Prostate Cell News Volume 11.45 | Nov 27 2020

    0
    165







    2020-11-27 | PCN 11.45


    Prostate Cell News by STEMCELL Technologies
    Vol. 11.45 – 27 November, 2020
    TOP STORY

    In Vitro-Transcribed Antigen Receptor mRNA Nanocarriers for Transient Expression in Circulating T Cells In Vivo

    In mouse models of human leukemia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated infusions of polymer nanocarriers induced sufficient host T cells expressing tumor-specific chimeric antigen receptors or virus-specific T cell receptors to cause disease regression at levels similar to bolus infusions of ex vivo engineered lymphocytes.
    [Nature Communications]

    Full Article

    Scientific resources to support your organoids research. Learn More!
    PUBLICATIONSRanked by the impact factor of the journal

    miR-199b-5p-DDR1-ERK Signaling Axis Suppresses Prostate Cancer Metastasis via Inhibiting Epithelial-Mesenchymal Transition

    Investigators demonstrated that miR-199b-5p was significantly downregulated in metastatic prostate cancer (PCa) tissues and cells when compared with the normal prostate tissue, the localized disease, the weakly metastatic and androgen-dependent PCa cell, and the normal prostate epithelial cell.
    [British Journal of Cancer]

    Abstract

    Inhibiting the P2X4 Receptor Suppresses Prostate Cancer Growth In Vitro and In Vivo, Suggesting a Potential Clinical Target

    Scientists demonstrated that inhibiting the P2X4 receptor impaired the growth and mobility of prostate cancer cells but not apoptosis. In BALB/c immunocompromised nude mice inoculated with human PC3 cells subcutaneously, 5-BDBD showed anti-tumourigenic effects.
    [Cells]

    Full ArticleGraphical Abstract

    Identification of Transcription Factor Co-Regulators that Drive Prostate Cancer Progression

    Researchers demonstrated an approach to identify cancer-driver coregulators in cancer, and that PGC1α expression is clinically significant yet underexplored coregulator in aggressive early stage prostate cancer.
    [Scientific Reports]

    Full Article

    microRNA-211-Mediated Targeting of the INHBA-TGF-β Axis Suppresses Prostate Tumor Formation and Growth

    Scientists indicated that upregulation of miR-211 has tumor-suppressive properties by inhibiting TGF-β pathway activation via inhibin-β A (INHBA) in prostate cancer stem cells.
    [Cancer Gene Therapy]

    Abstract

    Progression-Free Survival of Prostate Cancer Patients Is Prolonged with a Higher Regucalcin Expression in the Tumor Tissues: Overexpressed Regucalcin Suppresses the Growth and Bone Activity in Human Prostate Cancer Cells

    Overexpression of regucalcin in bone metastatic human prostate cancer PC-3 and DU-145 cells suppressed colony formation and cell growth in vitro. Overexpressed regucalcin enhanced the levels of p53, Rb, and p21, and decreased the levels of Ras, PI3 kinase, Akt, and mitogen-activated protein kinase, leading to suppression of cell growth.
    [Translational Oncology]

    Full Article

    18F-Fluciclovine PET Metabolic Imaging Reveals Prostate Cancer Tumor Heterogeneity Associated with Disease Resistance to Androgen Deprivation Therapy

    Isogenic androgen-responsive and castration-resistant human prostate cancer cells were implanted into the anterior lobes of the prostate in CD-1 Nu mice to generate prostate orthografts.
    [EJNMMI Research]

    Full Article

    Role of SPTSSB-Regulated De Novo Sphingolipid Synthesis in Prostate Cancer Depends on Androgen Receptor Signaling

    The authors demonstrated that elevating endogenous ceramide levels with administration of exogenous Ceramide Nanoliposomes was efficacious in androgen receptor (AR)-negative cell lines with limited efficacy in AR-positive cells.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer

    Investigators evaluated the potential effect of protein disulfide isomerase 4 on chemoresistance to docetaxel (DTX) in prostate cancer cells (DTX-resistant PC-3 cells and C4-2B cells) to investigate the underlying mechanisms.
    [Chemotherapy]

    Abstract

    Connect with us via LiveChat to ask your scientific support questions
    REVIEWS

    Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer

    The authors expand on the clinical development of PARP inhibitors (PARPis) in metastatic castration-resistant prostate cancer, discuss potential biomarkers that may predict successful tumor control, and summarize present and future clinical research on PARPis in the metastatic disease landscape.
    [Cancers]

    Full Article

    INDUSTRY AND POLICY NEWS

    Blue Earth Diagnostics Announces First Patient Doses of PET Imaging Agent rhPSMA-7.3 (18F) in Collaboration with Nucleis Radiopharmaceuticals in Liege, Belgium

    Blue Earth Diagnostics’ manufacturing partner, Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer and suspected prostate cancer recurrence.
    [Blue Earth Diagnostics]

    Press Release

    FEATURED EVENT

    Cell Symposia: 20 Years of the Human Genome: From Sequence to Substance

    April 11 – April 13, 2021
    San Diego, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Senior Investigator – Replication Stress and Chromatin Alterations

    NIH National Cancer Institute – Bethesda, Maryland, United States

    Postdoctoral Fellow – Advanced Prostate Cancer Therapies

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Postdoctoral Research Associate – Vancouver Prostate Centre, RNA Biology

    The University of British Columbia (UBC) – Vancouver, British Columbia, Canada

    Research Professional – Life Sciences

    Stanford University – Stanford, California, United States

    Senior Group Leader – Rare Cancers

    IRCCS Candiolo Cancer Institute – Candiolo, Italy

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter



    vvvv